Literature DB >> 15328125

SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.

Luiz E Bermudez1, Peter Kolonoski, Lianne E Seitz, Mary Petrofsky, Robert Reynolds, Martin Wu, Lowell S Young.   

Abstract

Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328125      PMCID： PMC514788          DOI： 10.1128/AAC.48.9.3556-3558.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial.

Authors:  A M Croft; T C Clayton; M J World
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Mar-Apr       Impact factor: 2.184

2.  In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex.

Authors:  C B Inderlied; P T Kolonoski; M Wu; L S Young
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

3.  Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS.

Authors:  L S Young; L Wiviott; M Wu; P Kolonoski; R Bolan; C B Inderlied
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

4.  Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.

Authors:  L E Bermudez; P Kolonoski; M Wu; P A Aralar; C B Inderlied; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Petrofsky; P Aralar; M Wu; L S Young
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 7.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

8.  Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team.

Authors:  R E Chaisson; C A Benson; M P Dube; L B Heifets; J A Korvick; S Elkin; T Smith; J C Craft; F R Sattler
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

9.  Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.

Authors:  Luiz E Bermudez; Robert Reynolds; Peter Kolonoski; Pricilla Aralar; Clark B Inderlied; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.

Authors:  Esteban C Nannini; Michael Keating; Peter Binstock; George Samonis; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2002-04       Impact factor: 6.072
View more
  9 in total

1.  6-Chloro-2-cyclo-propyl-4-(trifluoro-meth-yl)quinoline.

Authors:  H C Devarajegowda; H K Arunkashi; Suresh Babu Vepuri; N Chidananda; V D Jagadeesh Prasad
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-02-05

2.  Nicotinaldehyde [2,8-bis-(trifluoro-meth-yl)quinolin-4-yl]hydrazone monohydrate.

Authors:  H C Devarajegowda; Suresh Babu Vepuri; M Vinduvahini; H D Kavitha; H K Arunkashi
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-08-11

3.  3,4-Dimeth-oxy-benzaldehyde [2,8-bis-(trifluoro-meth-yl)quinolin-4-yl]hydrazone.

Authors:  Waleed Fedl Ali Al-Eryani; J Shylaja Kumari; H K Arunkashi; Suresh Babu Vepuri; H C Devarajegowda
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-06-23

4.  (R*,S*)-(±)-1-(2-{[2,8-Bis(trifluoromethyl)quinolin-4-yl](hydroxy)methyl}piperidin-1-yl)ethanone methanol monosolvate.

Authors:  Raoni S B Gonçalves; Marcus V N de Souza; Solange M S V Wardell; James L Wardell; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-09-30

Review 5.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

6.  Synthesis, anti-mycobacterial and cytotoxic evaluation of substituted isoindoline-1,3-dione-4-aminoquinolines coupled via alkyl/amide linkers.

Authors:  Anu Rani; Albertus Viljoen; Matt D Johansen; Laurent Kremer; Vipan Kumar
Journal:  RSC Adv       Date:  2019-03-13       Impact factor: 4.036

7.  Novel Organic Salts Based on Mefloquine: Synthesis, Solubility, Permeability, and In Vitro Activity against Mycobacterium tuberculosis.

Authors:  Dário Silva; Márcio V C Lopes; Željko Petrovski; Miguel M Santos; Jussevania P Santos; Sueli F Yamada-Ogatta; Marcelle L F Bispo; Marcus V N de Souza; Ana Rita C Duarte; Maria C S Lourenço; Raoni Schroeder B Gonçalves; Luis C Branco
Journal:  Molecules       Date:  2022-08-13       Impact factor: 4.927

8.  Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria.

Authors:  Anuradha Alahari; Xavier Trivelli; Yann Guérardel; Lynn G Dover; Gurdyal S Besra; James C Sacchettini; Robert C Reynolds; Geoffrey D Coxon; Laurent Kremer
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

9.  Imidazole-Thiosemicarbazide Derivatives as Potent Anti-Mycobacterium tuberculosis Compounds with Antibiofilm Activity.

Authors:  Adrian Bekier; Malwina Kawka; Jakub Lach; Jarosław Dziadek; Agata Paneth; Justyna Gatkowska; Katarzyna Dzitko; Bożena Dziadek
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.